Shenji Changhua Company, an enterprise transforming scientific and technological achievements of Tsinghua University and focusing on the distribution of neurological diseases such as ALS, has recently completed a seed round of financing of tens of millions, which is the exclusive investment of Beijing Life Science Park Innovation Investment Fund.
Nervous system diseases are the “hard bones” of the global gene therapy industry and one of the most important application fields of the gene therapy industry. At present, the clinical drugs for neurological diseases are extremely limited, and they are basically in a state of no drugs. Among them, ALS (Amyotrophic Lateral Sclerosis, abbreviated ALS) is one of the most malignant neurodegenerative diseases, and effective therapeutic drugs are urgently needed.
Data map Photo by Xinhua News Agency reporter Liu Chan
“Maybe there are only a few months left before I can fully communicate with you.” At the forum on the development of the gene therapy industry for neurological diseases, Cai Lei, the vice president of Jingdong Group, a patient with ALS, said in a slightly hoarse voice to the The participants exchanged their thoughts and experiences, and this calm tone but full of urgency deeply shocked the audience. Cai Lei’s report resonated strongly with the participants, and everyone had a heated discussion on ALS and rare diseases.
As representatives of scientists’ entrepreneurship, Professor Lu Bai of the School of Pharmacy of Tsinghua University, and Professor Lin Xin, Dean of the Department of Basic Medicine, pointed out that the advantage of university scientists is that they have been deeply involved in a sub-field for many years and can often obtain breakthrough original results. The transformation of achievements requires the formation of a talent team that pays equal attention to scientists, business operations and enterprise management talents to promote the transformation of innovative achievements. In this process, basic scientific research and industrial transformation can promote each other and develop together.
Wang Yuzhu, Assistant Dean of the Institute of Technology Transfer of Tsinghua University, introduced that Tsinghua University is constantly improving and encouraging the system and system for the transformation of basic scientific research into industry, and Shenji Changhua is a typical representative. It is understood that Shenji Changhua is located in Zhongguancun Life Science Park, Changping District, Beijing. It is a biotechnology company mainly engaged in the research and development of innovative drugs. The founding team is from Tsinghua University. The team focuses on ALS, mainly focusing on neurological diseases such as amyotrophic lateral sclerosis (ALS), stroke (Stoke), Parkinson’s disease (PD), Alzheimer’s disease (AD), especially neurodegenerative diseases , hoping to eventually solve these major medical and health problems for human beings. The chief scientist of the team and researcher Jia Yichang of Tsinghua University School of Medicine has been working silently in the field of ALS for nearly ten years, and has made major breakthroughs in new targets for ALS.
(Original title: Tsinghua Achievement Transformation Enterprise Receives Ten Million Investment)
Source: Beijing Daily Reporter: Sun Qiru
Process editor: u029